Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading pharmaceutical group operating across Central & Eastern Europe, today announce that the companies have entered into a long-term Licence, Distribution and Supply Agreement for AKYNZEO® (combination of netupitant-palonosetron) and ALOXI® (palonosetron) in Poland, Romania, Czech Republic, Slovakia and Hungary. Both products are indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients.
Riccardo Braglia, Chairman and CEO of Helsinn, commented: “We are pleased to welcome MagnaPharm, an established leader in the Central and Eastern European region, into our network of commercial partners. This collaboration marks an important milestone as we continue to expand access to our supportive care portfolio across key international markets. We look forward to working closely with the MagnaPharm team to ensure that a growing number of patients in the CEE region can benefit from these important therapies, which are designed to improve quality of life throughout the cancer care journey.”
Karol Michalak, CEO of MagnaPharm Group stated: “We are proud to embark on the partnerships with Helsinn, a globally respected leader in scientific innovation and patientcentered care – values that resonate deeply with our own mission. By joining forces, we strengthen our ability to expand access to innovative, high-impact therapies across the CEE region, ensuring that more patients benefit from the latest advances in oncology care. Through Akynzeo® and Aloxi®, we empower healthcare professionals with trusted, clinically proven solutions that not only enhance therapeutic outcomes, but also make a meaningful contribution to safeguarding patients’ quality of life throughout their cancer care and recovery.”
About AKYNZEO® AKYNZEO® is a 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.
About ALOXI® ALOXI® is approved in Europe in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. ALOXI® is also indicated in pediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
